A very high prevalence of low HDL cholesterol in Spanish patients with acute coronary syndromes

Clinical Cardiology

Volumn 33, Issue 7, 2010, Pages 418-423

  Pintó, Xavier ^a   Millán, Jesús ^b   Muñoz, Anna ^c   Corbella, Emili ^a   Hernández Mijares, Antonio ^d   Zuñiga, Manuel ^e   Mangas, Alipio ^f   Pedro Botet, Juan ^g  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Solvay Pharma   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^g HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; ISCHEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SEX DIFFERENCE; SPAIN; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DOWN REGULATION; DYSLIPIDEMIAS; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; DOWN-REGULATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PATIENT ADMISSION; PATIENT DISCHARGE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SPAIN; TIME FACTORS; TRIGLYCERIDES;

EID: 77954924983     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20774     Document Type: Article

References (35)

1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372. (Pubitemid 43947981)
2. Graham I, Atar D, Borch-Johnsen K, et al; ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007;194:1-45.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
4. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706-714.
5. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136 905 hospitalizations in Get with the Guidelines. Am Heart J. 2009;157:111-117.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
7. Ascaso JF, Fernández-Cruz A, González Santos P, et al. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. Am J Cardiovasc Drugs. 2004;4:299-314.
8. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-2838. (Pubitemid 17178361)
9. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105:1424-1428. (Pubitemid 34263272)
10. Knopp RH, Paramsothy P, Atkinson B, Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol. 2008;101(suppl): 48B-57B.
11. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293:1868-1874. (Pubitemid 40548183)
12. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
13. de Oya M. HDL cholesterol and cardiovascularmortality in Spain. Rev Esp Cardiol. 1998;51:988-990.
14. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000;21:1502-1513.
15. Thygesen K, Alpert JS, White HD; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-2538.
16. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951;11:480-493.
17. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
18. Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med. 2009;169:508-514.
19. Scott R, O'Brien R, Fulcher G, et al; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493-498.
20. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508. (Pubitemid 46220805)
21. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
22. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995;75:1196-1201.
23. The Bezafibrate Infarction Prevention (BIP) Study Group. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6700 men and 1500 women. Circulation. 1992;86:839-848.
24. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.
25. de Goma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patientswith low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49-55.
26. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
27. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992;70:733-737.
28. Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count? Atherosclerosis. 2005;180:217-223.
29. Cannon CP, Braunwald E, McCabe CH, et al; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
30. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
31. Jeffs JA, Godsland IF, Johnston DG. Less than 50% of variation in HDL cholesterol between and within individuals is explained by established predictors. Atherosclerosis. 2006;184:178-187.
32. Ghazzal ZB, Dhawan SS, Sheikh A, et al. Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol. 2009;103:902-906.
33. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-940.
34. Pfohl M, Schreiber I, Liebich HM, Häring HU, Hoffmeister HM. Upregulation of cholesterol synthesis after acute myocardial infarction - is cholesterol a positive acute phase reactant? Atherosclerosis. 1999;142:389-393. (Pubitemid 29059497)
35. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51:1440-1445.